H
Hele Everaus
Researcher at Tartu University Hospital
Publications - 52
Citations - 943
Hele Everaus is an academic researcher from Tartu University Hospital. The author has contributed to research in topics: Population & Relative survival. The author has an hindex of 13, co-authored 52 publications receiving 752 citations. Previous affiliations of Hele Everaus include National Institutes of Health & Sahlgrenska University Hospital.
Papers
More filters
Journal ArticleDOI
The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European Countries
Verena S. Hoffmann,Michele Baccarani,Joerg Hasford,Doris Lindoerfer,Sonja Burgstaller,Dubravka Sertić,Paul Costeas,Jiří Mayer,Karel Indrak,Hele Everaus,Perttu Koskenvesa,Joelle Guilhot,Gabriele Schubert-Fritschle,Fausto Castagnetti,F. Di Raimondo,Sandra Lejniece,Laimonas Griskevicius,Noortje Thielen,Tomasz Sacha,Andrzej Hellmann,Anna G. Turkina,Andrey Zaritskey,Andrija Bogdanovic,Zuzana Sninská,Irena Preloznik Zupan,J-L Steegmann,Bengt Simonsson,Richard E. Clark,A. Covelli,G. Guidi,Ruediger Hehlmann +30 more
TL;DR: The proportion of Sokal and Euro score high-risk patients seen in many countries indicates that trial patients were not a positive selection, and from a clinical point of view the results of most trials can be generalized to most countries.
Journal ArticleDOI
Systematic review of cytokines and growth factors for the management of oral mucositis in cancer patients
Judith E. Raber-Durlacher,Inger von Bültzingslöwen,Richard M. Logan,Joanne M. Bowen,Abdul Rahman Al-Azri,Hele Everaus,Erich Gerber,Jesùs Garcia Gomez,Bo G. Pettersson,Yoshihiko Soga,Fred K. L. Spijkervet,Wim J. E. Tissing,Joel B. Epstein,Sharon Elad,Rajesh V. Lalla,Isoo +15 more
TL;DR: The evidence only supports use of palifermin in the specific population studied for oral mucositis, and additional well-designed research is needed on other cytokine and growth factor interventions and in other cancer treatment settings.
Journal ArticleDOI
Phenotype-based drug screening reveals association between venetoclax response and differentiation stage in acute myeloid leukemia
Heikki Kuusanmäki,Aino-Maija Leppä,Petri Pölönen,Mika Kontro,Olli Dufva,Debashish Deb,Bhagwan Yadav,Oscar Brück,Ashwini Kumar,Hele Everaus,Bjørn Tore Gjertsen,Merja Heinäniemi,Kimmo Porkka,Satu Mustjoki,Caroline A. Heckman +14 more
TL;DR: It is shown that ex vivo efficacy of targeted agents and particularly Bcl-2 inhibitor venetoclax is influenced by the cell type, and accurate blast-specific drug responses can be assessed with a flow cytometry-based approach.
Journal ArticleDOI
Treatment and outcome of 2904 CML patients from the EUTOS population-based registry
Verena S. Hoffmann,Michele Baccarani,Joerg Hasford,Fausto Castagnetti,F. Di Raimondo,L.F. Casado,Anna G. Turkina,Daniela Zackova,Gert J. Ossenkoppele,Andrey Zaritskey,Martin Höglund,Bengt Simonsson,Karel Indrak,Zuzana Sninská,Tomasz Sacha,Richard E. Clark,Andrija Bogdanovic,Andrzej Hellmann,Laimonas Griskevicius,Gabriele Schubert-Fritschle,Dubravka Sertić,Joelle Guilhot,Sandra Lejniece,Irena Preloznik Zupan,Sonja Burgstaller,Perttu Koskenvesa,Hele Everaus,Paul Costeas,Doris Lindoerfer,Gianantonio Rosti,Susanne Saussele,Andreas Hochhaus,Ruediger Hehlmann +32 more
TL;DR: The new EUTOS long-term survival score was validated: the OS of patients differed significantly between the three risk groups, and the current management of patients with tyrosine kinase inhibitors resulted in responses and outcomes in the range reported from clinical trials.
Journal ArticleDOI
The effect of allogeneic stem cell transplantation on outcome in younger acute myeloid leukemia patients with minimal residual disease detected by flow cytometry at the end of post-remission chemotherapy.
Edward Laane,Åsa Rangert Derolf,E. Björklund,Joanna Mazur,Hele Everaus,Stefan Söderhäll,Magnus Björkholm,Anna Porwit-MacDonald +7 more
TL;DR: In this article, the minimal residual disease (MRD) levels were determined by multi-parameter flow cytometry in 45 younger adult patients (60 years old) with acute myeloid leukemia (AML) in complete remission.